公开(公告)号：US09522125B1

公开(公告)日：2016-12-20

申请号：US14945436

申请日：2015-11-19

Applicant: Macau University of Science and Technology

Inventor： Xiao-Jun Yao ,  Lai-Han Leung ,  Lian-Xiang Luo ,  Wen-Luan Hsiao ,  Liang Liu

IPC: A61K31/136

CPC classification number: A61K31/136

Abstract: The present invention discloses that a method of treating cancer, preferably non-small cell lung cancer, comprises administrating mitoxantrone. The present invention also discloses a method of inhibiting ROS1 kinase comprising administrating mitoxantrone. A pharmaceutical composition comprising mitoxantrone is also disclosed.

Abstract translation: 本发明公开了一种治疗癌症，优选非小细胞肺癌的方法，包括给予米托蒽醌。 本发明还公开了抑制ROS1激酶的方法，其包括施用米托蒽醌。 还公开了包含米托蒽醌的药物组合物。

公开(公告)号：US09597299B2

公开(公告)日：2017-03-21

申请号：US14624574

申请日：2015-02-17

Applicant: Macau University of Science and Technology

Inventor： Lai-Han Leung ,  Xing-Xing Fan ,  Liang Liu ,  Zebo Jiang

IPC: A61K31/661 ,  A61K31/09

CPC classification number: A61K31/09

Abstract: The present invention relates to a method for treating gefitinib-resistant non-small-cell lung cancer (NSCLC) comprising administering an effective amount of a resveratrol analog, (Z)3,4,5,4′-tetramethoxystilbene (TMS), to a subject in need thereof. The present invention also relates to a method for inducing apoptosis in gefitinib-resistant NSCLC cells comprising contacting the resveratrol analog to the cells at an effective amount. The present methods are mediated by different signaling pathways connected to cell proliferation and differentiation such as mTOR, JNK, and certain EGFR phosphorylated tyrosine kinase.

公开(公告)号：US09364469B1

公开(公告)日：2016-06-14

申请号：US14925996

申请日：2015-10-29

Applicant: Macau University of Science and Technology

Inventor： Lai-Han Leung ,  Xiao-Jun Yao ,  Kam Wai Wong ,  Liang Liu ,  Xi Chen

IPC: A61K31/4439

CPC classification number: A61K31/4439

Abstract: The present invention discloses a method of treating gefitinib-resistant non-small-cell lung cancer, comprising administering an effective amount of D561-0775. A pharmaceutical composition comprising D561-0775 admixed with a pharmaceutical carrier for treating Gefitinib-resistant non-small-cell lung cancer is also disclosed therein.

Abstract translation: 本发明公开了一种治疗耐吉非替尼的非小细胞肺癌的方法，包括给予有效量的D561-0775。 还公开了包含D561-0775的药物组合物，其与药物载体混合以治疗吉非替尼耐药性非小细胞肺癌。